Journal of Periodontal Research · 2008 · 53 citations · 39 references
DentistryPeriodontologyPharmacologyBone MetabolismPeriodontal MedicinePeriodontal TherapyAlveolar BoneAlveolar Bone ResorptionBone HealthBone Metabolism PharmacotherapyPeriodontal DiseasePeriodontal Tissue DestructionBone Resorption InhibitionBone Volume EvaluationDrug Effects On Bone DensityDrug-induced Bone LossOsteoclast-mediated Bone LossPeriapical Bone LossPeriodontal Bone ResorptionPeriodontitis-associated Bone Loss
BACKGROUND AND OBJECTIVE: Cyclosporine A treatment is important in the therapy of a number of medical conditions; however, alveolar bone loss is an important negative side-effect of this drug. As such, we evaluated whether concomitant administration of simvastatin would minimize cyclosporine A-associated alveolar bone loss in rats subjected, or not, to experimental periodontal disease. MATERIAL AND METHODS: Groups of 10 rats each were treated with cyclosporine A (10 mg/kg/day), simvastatin (20 mg/kg/day), cyclosporine A and simvastatin concurrently (cyclosporine A/simvastatin) or vehicle for 30 days. Four other groups of 10 rats each received a cotton ligature around the lower first molar and were treated similarly with cyclosporine A, simvastatin, cyclosporine A/simvastatin or vehicle. Calcium (Ca(2+)), phosphorus and alkaline phosphatase levels were evaluated in serum. Expression levels of interleukin-1beta, prostaglandin E(2) and inducible nitric oxide synthase were evaluated in the gingivomucosal tissues. Bone volume and numbers of osteoblasts and osteoclasts were also analyzed. RESULTS: Treatment with cyclosporine A in rats, with or without ligature, was associated with bone loss, represented by a lower bone volume and an increase in the number of osteoclasts. Treatment with cyclosporine A was associated with bone resorption, whereas simvastatin treatment improved cyclosporine A-associated alveolar bone loss in all parameters studied. In addition, simvastatin, in the presence of inflammation, can act as an anti-inflammatory agent. CONCLUSION: This study shows that simvastatin therapy leads to a reversal of the cyclosporine A-induced bone loss, which may be mediated by downregulation of interleukin-1beta and prostaglandin E(2) production.
39
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Gregory R. Mundy, R.J. Burriss Garrett, S. E. Harris et al. · Science · 1999 · 1.8K citations
Structural Mechanism for Statin Inhibition of HMG-CoA Reductase
Eva S. Istvan, J. Deisenhofer · Science · 2001 · 1.6K citations
Akira Endo, Yoshio Tsujita, Masao Kuroda et al. · European Journal of Biochemistry · 1977 · 263 citations · Full text